Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Earnings and Valuation
This table compares Verrica Pharmaceuticals and Jaguar Animal Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Verrica Pharmaceuticals | $35.58 million | 2.77 | -$17.89 million | ($1.03) | -5.56 |
| Jaguar Animal Health | $29.54 million | 0.05 | -$53.43 million | ($591.92) | 0.00 |
Profitability
This table compares Verrica Pharmaceuticals and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Verrica Pharmaceuticals | -47.97% | -1,077.78% | -40.76% |
| Jaguar Animal Health | -169.04% | -1,194.94% | -115.55% |
Volatility & Risk
Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500.
Insider and Institutional Ownership
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Jaguar Animal Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for Verrica Pharmaceuticals and Jaguar Animal Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Verrica Pharmaceuticals | 1 | 1 | 2 | 0 | 2.25 |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
Verrica Pharmaceuticals currently has a consensus price target of $14.50, indicating a potential upside of 153.05%. Given Verrica Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Jaguar Animal Health.
Summary
Verrica Pharmaceuticals beats Jaguar Animal Health on 13 of the 14 factors compared between the two stocks.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
